Institutional shares held 13.8 Million
0 calls
0 puts
Total value of holdings $4.54M
$0 calls
$0 puts
Market Cap $9.89M
29,982,300 Shares Out.
Institutional ownership 45.93%
# of Institutions 11


Latest Institutional Activity in PHGE

Top Purchases

Q1 2024
Ikarian Capital, LLC Shares Held: 10.8M ($3.57M)
Q1 2024
Deerfield Management Company, L.P. (Series C) Shares Held: 6.11M ($2.02M)
Q1 2024
Millennium Management LLC Shares Held: 19.8K ($6.52K)
Q1 2024
Jump Financial, LLC Shares Held: 19.2K ($6.34K)
Q1 2024
Concourse Financial Group Securities, Inc. Shares Held: 0 ($0)

Top Sells

Q1 2024
Johnson & Johnson Shares Held: 1.92M ($635K)
Q1 2024
Renaissance Technologies LLC Shares Held: 80.6K ($26.6K)
Q1 2024
Xtx Topco LTD Shares Held: 10.2K ($3.36K)
Q4 2023
Mmcap International Inc. Spc Shares Held: 96.8K ($31.9K)
Q4 2023
Orbimed Advisors LLC Shares Held: 4.52M ($1.49M)

About PHGE

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.


Insider Transactions at PHGE

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
20.2M Shares
From 3 Insiders
Grant, award, or other acquisition 6.11M shares
Exercise of in-the-money or at-the-money derivatives securities 14.1M shares
Sell / Disposition
35.3K Shares
From 2 Insiders
Open market or private sale 35.3K shares

Track Institutional and Insider Activities on PHGE

Follow BiomX Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PHGE shares.

Notify only if

Insider Trading

Get notified when an Biom X Inc. insider buys or sells PHGE shares.

Notify only if

News

Receive news related to BiomX Inc.

Track Activities on PHGE